GHWP Updates

Gao Guobiao
Vice-Chair, GHWP
Party Secretary, Center for Medical Device Evaluation
National Medical Products Administration
People's Republic of China

13th Sep 2022
IMDRF Stakeholder Open Forum
Table of Contents

01 Introduction of GHWP
02 GHWP TC Updates
03 GHWP in progress
• **Vision**
To Achieve International Harmonization of Medical Device Regulations through Collaborative Efforts of Regulators and the Industry.

• **Mission**
To Strategically Accelerate Medical Device Regulatory Convergence through Promotion of an Efficient and Effective Regulatory Model for Medical Devices.

• **Goals**
To develop and recommend approaches for the global convergence and harmonization of medical device regulations. To facilitate the exchange of knowledge and expertise amongst regulators and the industry for the establishment of harmonized requirements. To promote capacity building in members and to foster strategic membership expansion. To work in collaboration with related international organizations such as IMDRF, WHO, ISO, IEC, APEC, OECD.

---

**Organization structure**

- **GHWP**
  - Chair (Regulatory Authority)
  - Vice-Chair (Regulatory Authority)
  - Vice-Chair (Industry)
- **Capacity Building**
- **Secretariat Team**
- **GHWP Administration Services Limited (ASL)**
- **Technical Committee (TC)**
  - TC Chair (Regulatory Authority)
  - TC Co-Chair (Regulatory Authority)
  - TC Co-Chair (Industry)
- **Advisory Panel to TC**
- **Working Groups (WG1-WG9)**
• GHWP Member in the World

32 GHWP member countries or regions

GHWP member covered **56.82% population** in the world
As an Asian regional organization with linkage to GHTF (IMDRF later) (1998-2000)

GHWP is consist of the medical device regulatory authorities and the medical device industry

Guidance documents are formed by work groups

Focus on harmonize medical device regulations

Strong collaborations with each other

Established in 1990s
• GHWP UPDATES

25th Annual Meeting & 25th TC Meeting (30th Nov & 1st Dec 2021)

GHWP & APACMed Regulation Transformation (26th-27th May 2022)

New Proposal to be finalized
GHWP Strategic Framework Towards 2026 Strategic Objectives
GHWP New Organization to be discussed

Official Rebranding of AHWP into GHWP (1st Dec 2021)

New Guidance Documents
- Clinical Evidence for IVD Medical Devices - Clinical Performance Studies for In Vitro Diagnostic Medical Devices (by WG2 & WG5)
- Regulatory Mechanism for Medical Devices Including In Vitro Diagnostic Medical Devices and Software as Medical Devices During A Public Health Emergency (by WG1, WG2 & WG3)
- Replacement Reagent and Instrument Family Policy (by WG2)

Guidance Documents with IMDRF
In the near five years 10 guidance documents were issued, of which the four guidance documents were related to IMDRF Work Group documents.
GHWP TC

Work Group 1 (WG1) – Pre-Market Submission and CSDT

Work Group 2 (WG2) – Pre-market: IVDD

Work Group 3 (WG3) -Pre-market: Software as a Medical Device

Work Group 4 (WG4) – Post-market

Work Group 5 (WG5) – Clinical Evidence for Performance and Safety

Work Group 6 (WG6) – Quality Management System: Audit & Assessment

Work Group 7 (WG7) – Quality Management System: Operation & Implementation

Work Group 8 (WG8) – Standards

Work Group 9 (WG9) – UDI & Nomenclature
The 4-Step Procedure for Endorsement

**Step 1**
- **DRAFT**
  - Initiated by Chairs of Committees / WGs / STGs / Secretariat
  - For discussion within group members*

*Administrative requirement as reminded by GHWP Chair to submit NWIP Form to GHWP Leadership and/or TC Leadership for endorsement*

**Step 2**
- **PROPOSED**
  - Documents discussed in GHWP and/or TC Meetings
  - Post on GHWP website + circulations → Call for Comments

**Step 3**
- **PROPOSED FINAL**
  - Documents prepared for approvals and/or resolutions at annual meeting
  - Post on GHWP website + circulations

**Step 4**
- **FINAL**
  - Documents accepted, approved and/or passed resolutions
  - Available at GHWP web as GHWP official documents

**GHWP Final Documents**
(including Guidance Documents)
<table>
<thead>
<tr>
<th>Name</th>
<th>Description</th>
<th>Latest achievements</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WG1</strong></td>
<td>Pre-Market Submission and CSDT</td>
<td>1. Guidelines for use of electronic labels and electronic instructions for use (IFU) as the compliance supplementation of labels (in collaboration with WG2 and WG3); 2. The definition of patient customized products and applicable pre-marketing; 3. Guidelines for changes to a registered medical device (in collaboration with WG2).</td>
</tr>
<tr>
<td><strong>WG2</strong></td>
<td>Pre-market: IVDD</td>
<td>1. Label and registration change requirements of IVD reagents and registration requirements of a series of IVD reagent products applicable to the same instrument. 2. Related activities of international harmonization and standards organization within its scope of responsibility.</td>
</tr>
<tr>
<td><strong>WG3</strong></td>
<td>Pre-market: Software as a Medical Device</td>
<td>The requirements for application dossiers of independent software registration, the requirements for software cybersecurity, and the review and approval management of medical device software.</td>
</tr>
<tr>
<td><strong>WG4</strong></td>
<td>Post-market</td>
<td>Continuous updating and maintenance of the Post-marketing Resource Center</td>
</tr>
</tbody>
</table>
## GHWP TC UPDATES

<table>
<thead>
<tr>
<th>Name</th>
<th>Description</th>
<th>Latest achievements</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WG5</strong></td>
<td><strong>Clinical Evidence for Performance and Safety</strong></td>
<td>Clinical Evidence for IVD Medical Devices- Clinical Performance Studies for In Vitro Diagnostic Medical Devices. (1 Dec 2021)</td>
</tr>
<tr>
<td></td>
<td>Continuously monitoring the progress of clinical requirements of the International Organization for Standardization (including related work items of IMDRF, ISO 14155 and ISO 20916), and continuing to conduct situation analysis on the work contents of WG5</td>
<td></td>
</tr>
<tr>
<td><strong>WG6</strong></td>
<td><strong>Quality Management System: Audit &amp; Assessment</strong></td>
<td>Online training session: Co Chair Vincent Lam conducted remote audit technique (4 Feb 2021)</td>
</tr>
<tr>
<td></td>
<td>The effective implementation of the assessment of QMS in AHWP members</td>
<td></td>
</tr>
<tr>
<td><strong>WG7</strong></td>
<td><strong>Quality Management System: Operation &amp; Implementation</strong></td>
<td>QMS consideration for manufacturers and importers for localization</td>
</tr>
<tr>
<td></td>
<td>1. Making a comparison of similarities and differences between the related requirements of local QMS of each GHWP member in the ISO 13485; 2. Drafting guidelines related to QMS in the localization process of enterprises and importers.</td>
<td></td>
</tr>
<tr>
<td><strong>WG8</strong></td>
<td><strong>Standards</strong></td>
<td>Virtual Training: Medical Device Process Validation: The Need for a State of Art and Holistic Risk Based Approach (22 April 2021)</td>
</tr>
<tr>
<td><strong>WG9</strong></td>
<td><strong>UDI &amp; Nomenclature</strong></td>
<td>Seminar: UDI Regulation and Implementation Seminar (28th July 2021)</td>
</tr>
<tr>
<td></td>
<td>The main work of WG9 includes formulating UDI rules of GHWP on the basis of global harmonization, and obtaining an understanding of the UDI awareness among members.</td>
<td></td>
</tr>
</tbody>
</table>
• Guidelines to be adopted and implemented at the 26th annual meeting

WG 1, WG2 and WG3

• Guidelines for the Categorization of Changes to a Registered Medical Devices. (Newly revised)

WG8

• Medical Gas System – Recognized Essential Principles of Safety and Performance – Standards for Demonstrating Compliance.

WG9

• GHWP UDI Rules.

The other WGs

• e-IFU, change management, SaMD, etc.
• **GHWP in progress**

• **Several considerations to deepen the global harmonization work**

- Establish a sharing mechanism of regulatory information and optimal practices in member countries and regions under the framework of GHWP.

- Strengthen regulatory scientific research in such new fields as artificial intelligence, second-generation sequencing technology, 3D printing, cybersecurity, etc., so as to address the challenges brought by emerging technologies to medical device regulation.

- Actively participate in the formulation of international standards and regional regulatory coordination.

- Vigorously promote the capacity training program for regulatory authorities of GHWP.

- Establish a more inclusive strategic cooperation network, and join hands with international organizations, academic institutions and industries to ensure rapid access to innovative medical technologies.
Upcoming 26th GHWP Annual Meeting and GHWP TC Meeting

- Will be held in the Kingdom of Saudi Arabia for 4 days in mid-February 2023. (Subject to further web-announcement)
GHWP in progress

26th GHWP Annual Meeting and GHWP TC Meeting

**Achievement**
- New members
- New guidance documents

**Election**
- GHWP
- GHWP TC
- Work Groups

**Influence**
- International Org
- Region and Country
- International Conference
GHWP & China

Chengdu, China
China held the AHWP Annual Meeting for the first time.

2000
AHWP
AHWP determined its official work rules and the composition of members.

2007
China
China served as the rotating chairmanship of AHWP. During this period, the number of AHWP members increased to 22.

2007-2011
AHWP/GHWP
Official rebranding of AHWP into GHWP means transforming from Asia Focus initiatives to Global Presence of 32 members.

2021
China
NMPA shall make further efforts to support the work of GHWP and GHWP TC so as to promote and contribute Chinese wisdom.

2023-2026
Thank you

Please visit our website www.ghwp.info

• Stay tuned for new activities and updates
• Check out our guidance documents and give us comments
  • Welcome your joining to GHWP